Consolidated Q2 ended 30 Sep 2026: revenue up 43%, profit after tax up 80% year on year
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 ended 30 Sep 2026: revenue Rs 52,912 lakh, up 43%; profit after tax Rs 7,918 lakh, up 80% from year-earlier Rs 37,012 and Rs 4,407. EBITDA margin fell from 29.3% to 26.9%. Half-year consolidated: revenue Rs 99,490 lakh; PAT Rs 18,007 lakh. Exceptional charge: Rs 43 lakh. FTF Pharma entered insolvency proceedings on 9 Sep; excluding 22 days cut profit before tax by Rs 375 lakh. 2025 standalone figures restated after merger.
Revenue and profit growth may support the stock, but margin compression, exceptional costs and FTF Pharma insolvency proceedings add risk.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.